In the BioHarmony Drug Report Database

"Preview" Icon

Enasidenib

Idhifa (enasidenib) is a small molecule pharmaceutical. Enasidenib was first approved as Idhifa on 2017-08-01. It is used to treat myeloid leukemia acute in the USA. It is known to target isocitrate dehydrogenase [NADP], mitochondrial. Idhifa’s patents are valid until 2034-09-16 (FDA).

 

Trade Name

 

Idhifa
 

Common Name

 

enasidenib
 

ChEMBL ID

 

CHEMBL3989908
 

Indication

 

myeloid leukemia acute
 

Drug Class

 

Mutated isocitrate dehydrogenase (IDH) inhibitors

Image (chem structure or protein)

Enasidenib structure rendering